Earnings call transcript: Fulgent Genetics disappoints with Q1 2026 results By Investing.com

Fulgent Genetics reported Q1 2026 revenue of $71.1 million, down 3.2% year over year and below the $72.68 million estimate, while EPS of -$0.36 missed the -$0.11 forecast. Shares fell 1.25% premarket as management cited a large customer moving testing in-house, offset partially by $2.6 million from Bako/StrataDX and stronger biopharma growth. The company reiterated full-year 2026 revenue guidance of $350 million and flagged continued heavy buybacks, with 3.1 million shares repurchased year to date.

Analysis

FLGT’s print is less about a one-quarter miss and more about a forced portfolio reset: a single large account is being displaced, and the company is trying to replace that revenue with a more fragmented mix that carries better long-run concentration risk but worse near-term visibility. That usually creates a multi-quarter air pocket because the lost volume is not just revenue — it removes fixed-cost absorption, which mechanically pressures gross margin until the new base is filled.

The second-order winner is ILMN and other workflow-enabling vendors, not because they directly capture FLGT’s share, but because Fulgent is leaning harder into higher-throughput genomics, digital pathology, and AI-enabled lab ops to rebuild the base. The real competitive question is whether those investments drive true share gains or simply defend pricing in a crowded market; if utilization stays soft, the incremental tech stack can look like strategic progress while earnings remain structurally negative.

The cash/buyback story is important: repurchases are offsetting per-share damage, but they do not fix the operating hole. With a large pending tax refund and a sizable cash balance, the company has time, yet the market will likely price it as a “show me” story until there is clear evidence that the second half inflects without relying on backlog timing or one-off customer ramps.

Contrarian angle: the market may be underestimating how much of the disappointment is already in the stock after a large YTD drawdown, but it may still be overestimating the speed of recovery. The key catalyst window is the next 1-2 quarters: if volume stabilization and anatomic pathology integration show through, the name can re-rate sharply; if not, cash gets revalued less like a growth platform and more like a melting ice cube with optionality.

Key Decisions for Investors

• Stay short FLGT on any post-earnings bounce over the next 2-6 weeks; risk/reward favors fading rallies because the operating gap is likely to persist through at least Q2, and the stock remains vulnerable to another guidance credibility reset.
• For a cleaner expression, pair long ILMN vs short FLGT for the next 3-6 months; if FLGT keeps investing into genomics workflows, ILMN captures capex/tooling demand while FLGT bears the margin and execution burden.
• Sell FLGT upside via call spreads or covered calls into the next catalyst window (Q2 updates / ASCO-related commentary); the thesis is capped upside until proof of stabilization, while premium should remain elevated on event risk.
• If already long FLGT, reduce size and wait for evidence of Q2 revenue acceleration and margin normalization before re-entering; the risk/reward improves only if the customer-transition drag clearly bottoms.
• Watch for a tactical long only if revenue from the lost customer appears to stabilize and the gross margin snaps back toward management’s implied path; that would be a 1-2 quarter catalyst, not a secular conviction call.